AVENUE THERAPEUTICS INC (ATXI) Stock Price, Forecast & Analysis
USA - NASDAQ:ATXI - US05360L4032 - Common Stock
ATXI Key Statistics, Chart & Performance
The current stock price of ATXI is 0.42 USD. In the past month the price decreased by -69.78%. In the past year, price decreased by -96.3%.
ATXI Latest News, Press Relases and Analysis
ATXI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.43 | 820.57B | ||
| JNJ | JOHNSON & JOHNSON | 18.18 | 454.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.51 | 254.86B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.81 | 239.19B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.69 | 217.57B | ||
| MRK | MERCK & CO. INC. | 9.83 | 213.92B | ||
| PFE | PFIZER INC | 7.24 | 139.61B | ||
| SNY | SANOFI-ADR | 11.5 | 123.05B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.95 | 92.78B | ||
| ZTS | ZOETIS INC | 23.16 | 63.83B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 47.8 | 42.27B |
Related stock screener links
About ATXI
Company Profile
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 3 full-time employees. The company went IPO on 2017-06-27. The firm is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
Company Info
AVENUE THERAPEUTICS INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10036 US
CEO: Lucy Lu
Employees: 3
Phone: 17816524500
AVENUE THERAPEUTICS INC / ATXI FAQ
What does AVENUE THERAPEUTICS INC do?
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 3 full-time employees. The company went IPO on 2017-06-27. The firm is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
What is the stock price of AVENUE THERAPEUTICS INC today?
The current stock price of ATXI is 0.42 USD. The price decreased by -50.71% in the last trading session.
Does ATXI stock pay dividends?
ATXI does not pay a dividend.
What is the ChartMill rating of AVENUE THERAPEUTICS INC stock?
ATXI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is AVENUE THERAPEUTICS INC (ATXI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATXI.
ATXI Technical Analysis
ATXI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATXI. While ATXI seems to be doing ok healthwise, there are quite some concerns on its profitability.
ATXI Financial Highlights
Over the last trailing twelve months ATXI reported a non-GAAP Earnings per Share(EPS) of -19.25. The EPS increased by 83.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -360.69% | ||
| ROE | -362.76% | ||
| Debt/Equity | 0 |
ATXI Forecast & Estimates
7 analysts have analysed ATXI and the average price target is 8.16 USD. This implies a price increase of 1842.86% is expected in the next year compared to the current price of 0.42.